Filing Flows › Voyager Therapeutics (VYGR) › R&D spending
Voyager Therapeutics (VYGR) R&D spending by quarter
Voyager Therapeutics' R&D spending was $24.4M in Q3 2026 (third quarter 2026), +11% from Q2 2026. Over the last 7 quarters it ranged from $22.0M (Q2 2026) to $36.0M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $24.4M | +11% | -32% |
| Q2 2026 | $22.0M | -10% | -30% |
| Q1 2026 | $24.6M | -32% | -22% |
| Q4 2025 | $36.0M | +0.2% | — |
| Q3 2025 | $35.9M | +14% | — |
| Q2 2025 | $31.3M | -0.6% | — |
| Q1 2025 | $31.5M | — | — |
Q3 2026 at a glance
Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%, net loss $24.7M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Voyager Therapeutics' R&D spending?
Voyager Therapeutics' R&D spending was $24.4M in Q3 2026 (third quarter 2026), +11% from Q2 2026.
How has Voyager Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $22.0M (Q2 2026) to $36.0M (Q4 2025).